Published on HealthEconomics.com on January 3, 2018 As artificial intelligence (AI) and Big Data are lauded for their potential uses in life sciences and healthcare, it is becoming difficult to differentiate between the myriad of terms and technologies and their real value in advancing real-world evidence (RWE). In this article, we explore key AI[…]
January 30, 2018 – 11 am – 12 pm ET – Register Fibrotic diseases, such as non-alcoholic steatohepatitis (NASH), are responsible for 45% of US deaths a year. With a growing occurrence and few treatment options, more research is needed to better understand natural history and progression of these diseases, treatments and outcomes. This session[…]
November 28, 2017 – Dr. Richard Gliklich As artificial intelligence and advanced analytics are increasingly lauded for uses in life sciences and healthcare, it’s becoming difficult to differentiate between the different terms, to understand what is real and what is hype, and to understand how to best leverage these technologies for advancing real-world evidence and[…]
BIG DATA REVEALS 1 OUT OF 6 ER VISITS IN Q2 2017 OPIOID RELATED OM1 launches a prototype for tracking the public health crisis in near real time BOSTON, November 27, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced it has[…]
77% OF ADULT PATIENTS, SEEN BY HEALTHCARE PROVIDERS, NOW HAVE HIGH BLOOD PRESSURE OM1 releases big data analyses of impact of new blood pressure guidelines BOSTON, November 20, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced the release of big data[…]
